입체선택성 2,4,6-삼치환된 테트라하이드로파이란 유도체 및 이의 제조방법
    2.
    发明公开
    입체선택성 2,4,6-삼치환된 테트라하이드로파이란 유도체 및 이의 제조방법 有权
    二异氰酸酯选择性2,4,6-取代的四氢化Y嗪及其制备方法

    公开(公告)号:KR1020150109214A

    公开(公告)日:2015-10-01

    申请号:KR1020140032364

    申请日:2014-03-19

    CPC classification number: C07D309/04 C07D309/08 C07D309/24

    Abstract: 본발명은입체선택성 2,4,6-삼치환된테트라하이드로파이란유도체및 이의제조방법에관한것으로, 더욱상세하게는 2-메틸렌-1,4-다이올유도체를출발물질로하고루이스산촉매를이용한분자간고리화반응을수행하여, C2, C4 및 C6 위치에동시에치환기가도입된입체선택성 2,4,6-삼치환된테트라하이드로파이란유도체및 이의제조방법에관한것이다.

    Abstract translation: 本发明涉及立体选择性2,4,6-三取代四氢吡喃衍生物及其制备方法,更具体地说,涉及立体选择性2,4,6-三取代四氢吡喃衍生物及其制备方法,其中衍生物用途 2-亚甲基1,4-二醇衍生物作为原料,并使用路易斯酸催化剂进行分子间循环反应,其中取代基同时引入C_2,C_4和C_6的位置。

    미토콘드리아 기능 조절제로서의 아릴옥심 유도체
    3.
    发明授权
    미토콘드리아 기능 조절제로서의 아릴옥심 유도체 有权
    ARYLOXIME衍生物作为麻醉功能调节剂

    公开(公告)号:KR101267937B1

    公开(公告)日:2013-05-31

    申请号:KR1020120018465

    申请日:2012-02-23

    Abstract: PURPOSE: Aryloxime derivatives are provided to show excellent activity as a neuroprotective agent acting on mitochondria, therefore, to be useful as a treatment and prevention agent of diseases such as Alzheimer disease, Parkinson's disease, Huntington disease, ischemic disease, diabetes, and schizophrenia. CONSTITUTION: A chemical is selected from aryloxime derivatives represented by Chemical formula 1, and pharmaceutically acceptable salt thereof. In the chemical formula 1; R^1 represents a 4-8 membered azacyclic group or a 7-9 membered azabicylic group, and the azacyclic or azabicyclic group is able to be substituted with 1-3 substituents selected from C1-6 alkyl and benzyl, or be non-substituted; R^2 and R^3 respectively represent a hydrogen group, a halogen group, a C1-C6 alkyl group, a C1-C6 haloalkyl group, or a C1-C6 alkoxy group; and n is an integer of 0, 1, 2 or 3.

    Abstract translation: 目的:提供芳肟衍生物作为作用于线粒体的神经保护剂具有优异的活性,因此可用作诸如阿尔茨海默病,帕金森病,亨廷顿病,缺血性疾病,糖尿病和精神分裂症等疾病的治疗和预防剂。 构成:选自化学式1表示的芳肟衍生物及其药学上可接受的盐。 在化学式1中; R 1表示4-8元氮杂环基或7-9元氮杂双环基,氮杂环或氮杂双环基团可以被1-3个选自C 1-6烷基和苄基的取代基取代,或被取代 ; R 2和R 3分别表示氢基,卤素基,C 1 -C 6烷基,C 1 -C 6卤代烷基或C 1 -C 6烷氧基; n为0,1,2或3的整数。

Patent Agency Ranking